DODGE & COX — CVS HEALTH CORP CVS: Quarterly 13F Position History
DODGE & COX has reported CVS HEALTH CORP (CVS) on 41 13F-HR filings in Pactolio's tracked window, first appearing in Q1 2016. As of Q1 2026, the position is sized at 51,780,116 shares ($3.72B market value, 2.04% of the equity book). Quarter-over-quarter share count change: 10,729,872 (-17.2%) .
- 51,780,116Shares Held (Latest Filing)
- $3.72BReported Market Value (Latest Filing)
- 2.04%Portfolio Weight (% of 13F Equity Book)
- 10,729,872Quarter-over-Quarter Share Change
- -$1.24BQuarter-over-Quarter Value Change
- 73,459,122Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 51,780,116 | 10,729,872 | -17.2% | $3.72B | 2.04% | $71.82 |
| Q4 2025 | 62,509,988 | 10,666,598 | -14.6% | $4.96B | 2.68% | $79.36 |
| Q3 2025 | 73,176,586 | 112,180 | -0.2% | $5.52B | 2.98% | $75.39 |
| Q2 2025 | 73,288,766 | 170,356 | -0.2% | $5.06B | 2.84% | $68.98 |
| Q1 2025 | 73,459,122 | +3,353,223 | +4.8% | $4.98B | 2.84% | $67.75 |
| Q4 2024 | 70,105,899 | +7,075,209 | +11.2% | $3.15B | 1.83% | $44.89 |
| Q3 2024 | 63,030,690 | +1,347,347 | +2.2% | $3.96B | 2.24% | $62.88 |
| Q2 2024 | 61,683,343 | +20,670,800 | +50.4% | $3.64B | 2.19% | $59.06 |
| Q1 2024 | 41,012,543 | +10,599,153 | +34.9% | $3.27B | 1.90% | $79.76 |
| Q4 2023 | 30,413,390 | +3,690,408 | +13.8% | $2.40B | 1.53% | $78.96 |
| Q3 2023 | 26,722,982 | +10,698,560 | +66.8% | $1.87B | 1.26% | $69.82 |
| Q2 2023 | 16,024,422 | +3,417,573 | +27.1% | $1.11B | 0.74% | $69.13 |
| Q1 2023 | 12,606,849 | +5,962 | +0.0% | $936.8M | 0.64% | $74.31 |
| Q4 2022 | 12,600,887 | 871,885 | -6.5% | $1.17B | 0.81% | $93.19 |
| Q3 2022 | 13,472,772 | 236,945 | -1.7% | $1.28B | 0.97% | $95.37 |
| Q2 2022 | 13,709,717 | 360,565 | -2.6% | $1.27B | 0.88% | $92.66 |
| Q1 2022 | 14,070,282 | 543,390 | -3.7% | $1.42B | 0.87% | $101.21 |
| Q4 2021 | 14,613,672 | 676,550 | -4.4% | $1.51B | 0.93% | $103.16 |
| Q3 2021 | 15,290,222 | 432,852 | -2.8% | $1.30B | 0.85% | $84.86 |
| Q2 2021 | 15,723,074 | 441,911 | -2.7% | $1.31B | 0.86% | $83.44 |
| Q1 2021 | 16,164,985 | +204,512 | +1.3% | $1.22B | 0.87% | $75.23 |
| Q4 2020 | 15,960,473 | +77,629 | +0.5% | $1.09B | 0.86% | $68.30 |
| Q3 2020 | 15,882,844 | 118,894 | -0.7% | $927.6M | 0.85% | $58.40 |
| Q2 2020 | 16,001,738 | 4,862,218 | -23.3% | $1.04B | 0.96% | $64.97 |
| Q1 2020 | 20,863,956 | +368,385 | +1.8% | $1.24B | 1.34% | $59.33 |
| Q4 2019 | 20,495,571 | 357,601 | -1.7% | $1.52B | 1.17% | $74.29 |
| Q3 2019 | 20,853,172 | +162,868 | +0.8% | $1.32B | 1.08% | $63.07 |
| Q2 2019 | 20,690,304 | +842,140 | +4.2% | $1.13B | 0.91% | $54.49 |
| Q1 2019 | 19,848,164 | +3,799,275 | +23.7% | $1.07B | 0.88% | $53.93 |
| Q4 2018 | 16,048,889 | +923,203 | +6.1% | $1.05B | 0.96% | $65.52 |
| Q3 2018 | 15,125,686 | +15,125,686 | — | $1.19B | 0.92% | $78.72 |
| Q2 2018 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2018 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2017 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2017 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2017 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2017 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2016 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2016 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2016 | 0 | 2,630 | -100.0% | $0 | 0.00% | — |
| Q1 2016 | 2,630 | — | — | $273.0K | 0.00% | $103.80 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did DODGE & COX first disclose a CVS position in 13F-HR filings?
DODGE & COX first reported CVS HEALTH CORP (CVS) on its 13F-HR filing for the period ending 2016-03-31 (Q1 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was DODGE & COX's most recent quarter-over-quarter share-count change in CVS?
Between Q4 2025 and Q1 2026, DODGE & COX reduced its CVS position by 10,729,872 shares (-17.2%), leaving 51,780,116 shares at a market value of $3.72B.
Does the implied price-per-share represent DODGE & COX's cost basis in CVS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.